NASDAQ: CYTK | Healthcare / Biotechnology / USA |
27.88 | -1.58 | -5.36% | Vol 1.33M | 1Y Perf -39.20% |
Oct 2nd, 2023 16:00 DELAYED |
BID | 27.00 | ASK | 29.07 | ||
Open | 29.36 | Previous Close | 29.46 | ||
Pre-Market | - | After-Market | 27.88 | ||
- - | - -% |
Target Price | 62.36 | Analyst Rating | Strong Buy 1.29 | |
Potential % | 123.67 | Finscreener Ranking | ★+ 44.45 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★ 40.03 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★+ 40.73 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | -4.61 | Earnings Rating | Strong Buy | |
Market Cap | 2.68B | Earnings Date | 2nd Nov 2023 | |
Alpha | 0.03 | Standard Deviation | 0.16 | |
Beta | 0.74 |
Today's Price Range 27.5629.40 | 52W Range 28.9652.40 | 5 Year PE Ratio Range -8.8050.60 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -7.07% | ||
1 Month | -22.56% | ||
3 Months | -16.43% | ||
6 Months | -26.07% | ||
1 Year | -39.20% | ||
3 Years | 16.22% | ||
5 Years | 200.11% | ||
10 Years | 296.59% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -115.12 | |||
ROE last 12 Months | -289.41 | |||
ROA (5Y Avg) | -12.71 | |||
ROA last 12 Months | -31.76 | |||
ROC (5Y Avg) | -65.11 | |||
ROC last 12 Months | -39.38 | |||
Return on invested Capital Q | -22.56 | |||
Return on invested Capital Y | -4.22 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 3.90 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-13.80 | ||||
31.90 | ||||
43.21 | ||||
409.20 | ||||
-19.50 | ||||
-2.82 | ||||
-255.58 | ||||
-0.17 | ||||
3.95B | ||||
Forward PE | -7.73 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
11.40 | ||||
11.60 | ||||
0.74 | ||||
2.91 | ||||
-5.50 | ||||
Leverage Ratio | 13.40 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-241.80 | ||||
-161.10 | ||||
-157.80 | ||||
-405.90 | ||||
-99.17 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
92.63M | ||||
0.98 | ||||
30.92 | ||||
12.23 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -1.23 | -1.34 | -8.94 |
Q01 2023 | -1.24 | -1.38 | -11.29 |
Q04 2022 | -1.22 | -1.45 | -18.85 |
Q03 2022 | -1.19 | -1.28 | -7.56 |
Q02 2022 | -1.04 | -0.23 | 77.88 |
Q01 2022 | -0.93 | -1.02 | -9.68 |
Q04 2021 | -0.89 | -0.36 | 59.55 |
Q03 2021 | -0.75 | -0.95 | -26.67 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | -0.72 | 30.10 | Positive |
12/2023 QR | -0.75 | 7.41 | Positive |
12/2023 FY | -4.10 | 6.39 | Positive |
12/2024 FY | -3.81 | 10.77 | Positive |
Next Report Date | 2nd Nov 2023 |
Estimated EPS Next Report | -0.72 |
Estimates Count | 10 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1.33M |
Shares Outstanding | 96.00K |
Shares Float | 92.35M |
Trades Count | 18.11K |
Dollar Volume | 37.53M |
Avg. Volume | 878.27K |
Avg. Weekly Volume | 1.11M |
Avg. Monthly Volume | 794.55K |
Avg. Quarterly Volume | 733.80K |
Cytokinetics Incorporated (NASDAQ: CYTK) stock closed at 27.88 per share at the end of the most recent trading day (a -5.36% change compared to the prior day closing price) with a volume of 1.33M shares and market capitalization of 2.68B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 156 people. Cytokinetics Incorporated CEO is Robert I. Blum.
The one-year performance of Cytokinetics Incorporated stock is -39.2%, while year-to-date (YTD) performance is -39.15%. CYTK stock has a five-year performance of 200.11%. Its 52-week range is between 28.96 and 52.4013, which gives CYTK stock a 52-week price range ratio of -4.61%
Cytokinetics Incorporated currently has a PE ratio of -13.80, a price-to-book (PB) ratio of 31.90, a price-to-sale (PS) ratio of 43.21, a price to cashflow ratio of 409.20, a PEG ratio of -, a ROA of -31.76%, a ROC of -39.38% and a ROE of -289.41%. The company’s profit margin is -99.17%, its EBITDA margin is -157.80%, and its revenue ttm is $92.63 Million , which makes it $0.98 revenue per share.
Of the last four earnings reports from Cytokinetics Incorporated, there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Cytokinetics Incorporated’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for Cytokinetics Incorporated is Strong Buy (1.29), with a target price of $62.36, which is +123.67% compared to the current price. The earnings rating for Cytokinetics Incorporated stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cytokinetics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cytokinetics Incorporated has a Sell technical analysis rating based on Technical Indicators (ADX : 9.79, ATR14 : 1.32, CCI20 : -138.05, Chaikin Money Flow : -0.33, MACD : -1.33, Money Flow Index : 11.39, ROC : -18.50, RSI : 26.33, STOCH (14,3) : 4.15, STOCH RSI : 0.00, UO : 31.17, Williams %R : -95.85), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cytokinetics Incorporated in the last 12-months were: Blum Robert (Option Excercise at a value of $2 107 200), Blum Robert (Sold 230 000 shares of value $8 906 725 ), Blum Robert I (Option Exercise at a value of $120 625), Blum Robert I (Sold 12 500 shares of value $463 250 ), Ching W. Jaw (Sold 0 shares of value $-181 500 ), Ching W. Jaw (Sold 15 000 shares of value $675 000 ), Fady I. Malik (Option Excercise at a value of $319 040), Fady I. Malik (Sold 66 300 shares of value $2 783 546 ), Fady Ibraham Malik (Option Excercise at a value of $263 320), Fady Ibraham Malik (Sold 52 513 shares of value $2 250 634 ), Henderson John (Option Excercise at a value of $28 245), Henderson John (Sold 4 166 shares of value $157 350 ), Robert C. Wong (Sold 7 338 shares of value $321 607 ), Robert I. Blum (Option Excercise at a value of $988 013), Robert I. Blum (Sold 107 500 shares of value $4 475 995 ), Wendall Wierenga (Option Excercise at a value of $87 494), Wendall Wierenga (Sold 13 020 shares of value $507 760 ), Wendell D. Wierenga (Option Excercise at a value of $47 040), Wendell D. Wierenga (Sold 7 000 shares of value $315 000 ), Wong Robert (Sold 7 338 shares of value $321 607 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatment for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility.
CEO: Robert I. Blum
Telephone: +1 650 624-3000
Address: 280 East Grand Avenue, South San Francisco 94080, CA, US
Number of employees: 156
Mon, 25 Sep 2023 11:00 GMT Analysts Top Healthcare Picks: Cytokinetics (CYTK), Amgen (AMGN)
- TipRanks. All rights reserved.Fri, 22 Sep 2023 10:31 GMT Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and CymaBay Therapeutics (CBAY)
- TipRanks. All rights reserved.Fri, 28 Jul 2023 20:05 GMT Cytokinetics (CYTK) Receives a Buy from Mizuho Securities
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.